EXOD 200
Exod 200mg Tablet contains Ofloxacin 200 mg, an antibiotic used to treat various bacterial infections such as UTIs, respiratory infections, and skin infections. It works by inhibiting bacterial growth. Common side effects include nausea, headache, and dizziness. Take as prescribed, with or without food, and avoid sun exposure during treatment.
₨75.00
Ask about productDescription
Uses
- Urinary Tract Infections (UTIs): Including uncomplicated cystitis and complicated UTIs
- Respiratory Tract Infections: Such as community-acquired pneumonia and chronic bronchitis
- Skin and Soft Tissue Infections
- Pelvic Inflammatory Disease
- Uncomplicated Gonorrhea
- Typhoid Fever
- Traveler’s Diarrhea
- Prostatitis
- Leprosy
- Anthrax
- Legionnaire’s Disease
Dosage
- Adults: Typically, 200 mg twice daily for 3–7 days for uncomplicated UTIs; 200 mg twice daily for 10 days for complicated UTIs.
- Renal Impairment: Dosage adjustment may be necessary for patients with renal issues.
Administration
- Take the tablet whole, with or without food.
- Avoid antacids or supplements containing iron, zinc, or calcium within 2 hours before or after taking the medication.
Side Effects
- Common: Nausea, headache, dizziness, insomnia, diarrhea, abdominal pain.
- Serious (Rare): Tendon rupture, seizures, liver damage, allergic reactions, QT interval prolongation.
Precautions
- Pregnancy & Breastfeeding: Consult a doctor before use.
- Kidney/Liver Issues: Use with caution; dosage adjustment may be necessary.
- Seizure Disorders: Not recommended for individuals with a history of epilepsy or other CNS disorders.
- Sun Sensitivity: May increase sensitivity to sunlight; avoid prolonged exposure.
Substitutes
- Oflofine 200mg Tablet
- Zanocin 200mg Tablet
- Floxal 200mg Tablet
- Terflox 200mg Tablet
Storage
- Store below 30°C in a dry, cool place.
- Keep away from direct sunlight and moisture.
- Keep out of reach of children.
Additional information
form | Oral Tablets |
---|
Be the first to review “EXOD 200” Cancel reply
Reviews
There are no reviews yet.